SEO, content and campaigns built around what your category is actually allowed to say, and to whom.
Generic marketing advice assumes you can publish whatever converts. Pharmaceutical marketing starts from the opposite constraint: what is approved, what platforms actually permit for this category, and how fast your medical review can move — and finds real visibility inside that boundary rather than around it.
See pharmaceutical SEO for how the keyword and content strategy is built from your approved claims outward, not fitted to them after the fact.
Most platforms restrict prescription drug advertising significantly — see pharmaceutical paid media for what is genuinely achievable by category and market before any budget is spent.
A content calendar sized for a consumer brand collides with medical review and produces a backlog, not more published content — every content service here is scoped against what your reviewers can actually sustain.
See AI search visibility for how content is structured so AI-generated answers can cite it accurately, alongside the classic ranking work — increasingly, the first result a prescriber or patient sees is a generated summary, not a blue link, and a page that was never built to be extracted from will not appear in it.
See international SEO for how one core content strategy is adapted market by market without each local team rebuilding it from scratch or drifting from what was actually approved centrally.
Every marketing service we provide, from SEO and content to paid media and CRM.
No, every claim originates with your medical and regulatory function, not with us. We write, structure and format the content around what has already been approved, translating cleared claims into copy that fits the channel — web page, email, or campaign — without introducing new statements that would need a fresh approval cycle.
A general agency treats medical and legal review as a delay to work around; here it is the starting constraint every plan, calendar and piece of content is built inside from the beginning, which is why content rarely gets rejected late.
Most engagements sit alongside an in-house team — we typically own the specialist execution (SEO, paid media, content production) while your team keeps strategy and stakeholder management, and we agree the split explicitly before work starts rather than assuming it.
Yes, running several markets in parallel is a normal part of the work, not an add-on. We build one consistent strategy and set of assets, then adapt language, channels and claims per market so each launch reuses what already works rather than starting from scratch. See international SEO and omnichannel strategy for how that structure holds together across markets.
Both. We plan the content strategy — topics, cadence, channel mix — and write the pieces themselves, because splitting the two across separate suppliers usually creates gaps where strategy and execution drift apart. See content marketing and medical copywriting for how the writing work runs alongside the planning rather than as a separate, later phase.
Cadence is set by your medical and legal review capacity, not by an ideal publishing schedule we impose. We map how long your review cycle takes, then build a realistic content calendar around it, rather than committing to a frequency that stalls once review becomes the bottleneck. See how to speed up MLR for web content for ways to shorten that cycle itself.
Tell us your situation and we will tell you how we would approach it.